GO
Loading...

Enter multiple symbols separated by commas

FDA

More

  • 10 drugs to hit fed budget by $50B over decade Tuesday, 9 Jun 2015 | 1:42 PM ET
    Health Care

    Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.

  • FDA targets 'bad' cholesterol drug Tuesday, 9 Jun 2015 | 6:31 AM ET
    FDA targets 'bad' cholesterol drug

    CNBC's Meg Tirrell reports the FDA meets today and tomorrow to discuss and vote on recommendation for approval of new cholesterol drugs, Praluent and Repatha.

  • June 8- Biotechnology company Neurocrine Biosciences Inc said it had suspended two planned clinical trials of its experimental drug to treat a potentially life-threatening genetic disorder called congenital adrenal hyperplasia. The U.S. Food and Drug Administration has informed Neurocrine that the drug's development program would be placed on...

  • WASHINGTON, June 5- An experimental drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday before a meeting on Tuesday of a panel of outside advisers to the FDA who will discuss...

  • For Paion AG, that's an opportunity. Paion says that will give its proprietary drug an edge over two established anesthetics, which have long since come off patent and are available as low-cost generics. Paion is pushing for the drug, now being tested on patients undergoing colonoscopies, to be approved by the U.S. Food and Drug Administration for use without an...

  • WASHINGTON, June 5- A drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday on the FDA's website before a meeting Tuesday of a panel of outside advisers who will discuss the drug...

  • FDA panel approves 'female Viagra' drug Friday, 5 Jun 2015 | 7:55 AM ET
    FDA panel approves 'female Viagra' drug

    CNBC's Meg Tirrell reports on the woman's libido drug.

  • 'Female Viagra' drug gets FDA panel support Friday, 5 Jun 2015 | 4:38 AM ET
    Prescription drugs

    A drug to treat low female sexual desire should be approved with strict measures to ensure patients are aware of its risks, an FDA panel concluded.

  • The FDA has twice rejected the drug, flibanserin, made by privately held Sprout Pharmaceuticals. Palatin estimates the combined global market for the two drugs at between $1.5 billion and $2 billion. The panel's recommendation follows months of lobbying by Sprout, aided by a number of women's advocacy groups which accused the FDA of gender bias since the...

  • WASHINGTON, June 4- A drug to treat low female sexual desire should be approved with strict measures in place to ensure patients are fully aware of its risks, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The FDA, which has twice rejected the drug, flibanserin, is not obliged to follow the advice of its advisory panels but typically...

  • FDA panel backs approval of women's libido drug Thursday, 4 Jun 2015 | 4:19 PM ET

    WASHINGTON, June 4- A drug to treat low female sexual desire should be approved with strict procedures in place to ensure patients are fully aware of its risks, including fainting and low blood pressure, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The FDA, which has twice rejected the drug, flibanserin, is not obliged to follow...

  • 'Female Viagra' up for consideration again Thursday, 4 Jun 2015 | 7:00 AM ET
    'Female Viagra' up for consideration again

    The FDA is again considering approval for Fibanserin, "the female Viagra."

  • These are the 9 worst chain restaurant meals Wednesday, 3 Jun 2015 | 12:17 PM ET
    Red Lobster in Times Square, New York.

    Get prepared to hit the treadmill after eating these calorie-laden dishes.

  • The FDA typically follows the advice of its advisory panels. The FDA review found a statistically significant improvement in the number of satisfying sexual events experienced by women taking the drug and a reduction in distress related to low desire. The differences were numerically small, however, and the question remains whether the drug's benefits...

  • Altria Group Inc, Reynolds American Inc and Lorillard Inc dismissed their case after the FDA on May 29 said it would review whether to mandate advance approval for label alterations such as changes to logos and background colors, or the use of descriptors such as "premium tobacco." In their April lawsuit filed in federal court in Washington, D.C., the companies said...

  • Tobacco companies drop lawsuit vs FDA over labeling Tuesday, 2 Jun 2015 | 1:27 PM ET

    In a filing with the federal court in Washington, D.C., units of Altria Group Inc, Reynolds American Inc and Lorillard Inc said they decided to dismiss their case after the FDA on May 29 said it would review a policy governing the labeling of tobacco products.

  • FDA panel to discuss Lilly's lung cancer drug approval Tuesday, 2 Jun 2015 | 11:10 AM ET

    June 2- The U.S. Food and Drug Administration said a panel of experts would discuss a marketing application from Eli Lilly& Co on a new targeted lung cancer treatment. The FDA said the panel would review data that showed improved overall survival rate in lung cancer patients treated with a combination of Lilly's experimental drug, necitumumab, and chemotherapy...

  • The review, published on the FDA's website on Tuesday, comes two days before a meeting of external advisers who will discuss the drug and recommend whether it should be approved. The FDA typically follows the advice of its advisory panels. The difference was numerically small, however, and the question remains whether the drug's benefits outweigh the risks, the...

  • June 2- A drug to increase sexual desire in women showed a statistically significant benefit, according to a preliminary review by the U.S. Food and Drug Administration, but the agency raised concerns about an increased risk of fainting and falling blood pressure. "The fundamental question is whether these observed placebo-corrected treatment effects...

  • 'Viagra for women' gets push for FDA approval Monday, 1 Jun 2015 | 12:02 PM ET
    A tablet of flibanserin at Sprout Pharmaceuticals in Raleigh, N.C.

    A campaign accuses the FDA of gender bias for approving drugs to help men have sex, but none for women. The NYT reports.